Gufic Biosciences · NSE: GUFICBIO · BSE: 509079
Q3 FY22 results · Oct–Dec 2021
Gufic Biosciences reported revenue from operations of ₹172.07 crore (up 19.2% from Q3 FY21) and net profit of ₹21.03 crore (up 59.6% from Q3 FY21) for Q3 FY22 (Oct–Dec 2021), on a standalone basis.
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 172.07 | 144.41 | +19.2% | 194.14 | −11.4% |
| Other income | 1.53 | 0.60 | +156.8% | 0.30 | +401.7% |
| Total income | 173.60 | 145.01 | +19.7% | 194.44 | −10.7% |
| Profit before tax | 28.73 | 18.17 | +58.1% | 30.39 | −5.5% |
| Net profit for the period | 21.03 | 13.18 | +59.6% | 23.34 | −9.9% |
| EPS, basic (₹) | 2.17 | 1.69 | not comparable | 2.41 | −9.8% |
| Net margin (%) | 12.2 | 9.1 | 12.0 |
Standalone
- Filed with BSE
- 10 Feb 2022, 14:14 IST
- Board meeting
- 09 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE